Our Commitment to Transparency

We are committed to maintaining transparent and timely communication with our shareholders through comprehensive disclosures, legal documents, and ownership patterns. Our investor resources provide complete visibility into shareholding structures, regulatory filings, and corporate actions to support informed investment decisions and ensure compliance with all statutory requirements.

Our Commitment to Transparency

Shareholder Resources

Select Resource

Ownership distribution and shareholding changes over different reporting periods.

Quarter Download
Q1 (Apr-Jun)
Q2 (Jul-Sep)
Q3 (Oct-Dec)
Q4 (Jan-Mar)

Official shareholder communications, regulatory disclosures, and statutory notices.

Report Name Download
Press Release Sumatriptan Injection
Press Release Dasatinib Tablets
Conversion into WhollyOwned Subsidiary Alembic Pharmaceuticals Scientific Office L.L.C., 6th November, 2025
Related Party Transaction for the quarter ended 30th September, 2025
Intimation Under Regulation 30 Newspaper Publication Of The Financial Results For The Quarter Ended 30th September, 2025
Press Release Ticagrelor Tablets
Intimation of Investor Meet, 4th November, 2025
Press Release Triamcinolone Acetonide Injectable Suspension
Intimaiton of BM, 4th November, 2025
Intimation Under Regulation 30 Newspaper Publication Of Special Window For Re-Lodgement Of Transfer Requests Of Physical Shares
Intimation Under Regulation 30 Newspaper Publication Of Saksham Niveshak
Intimation for Change in Email Address of the RTA of the Company
Press Release for Paroxetine Extended-Release Tablets USP, 25 mg and 37.5 mg
Intimation Under Regulation 30 Loss Of Share Certificate Dated 15th September, 2025
Alembic Pharmaceuticals Limited receives EIR for API-I & API-II, Panelav
Press Release for Phytonadione Injectable Emulsion
Intimation of Investor Meet, 29th August, 2025 Signed
Press Release for Macitentan Tablets
Intimation of Investor Meet, 22nd August, 2025
Intimation of Investor Meet, 18th August, 2025
Press Release For Tretinoin Cream USP
Intimation under Regulation 30 Newspaper Publication of the Financial Results for the Quarter ended June, 2025
Contact Details of Key Managerial Personnel Senior Officials
SE Intimation SMP, 31st July, 2025
Press Release for Carbamazepine Extended-Release Tablets
Intimation of Credit Rating of Enhanced Amount of Bank Loans, CRISIL
Intimation of Investor Meet, 5th August, 2025
Intimation of BM, 5th August, 2025
SE Intimation SMP, 21st July, 2025
SE Intimation SMP, 8th July 2025
Intimation for Relinquishment of CFO of the Company
Intimation for Appointment of CFO of the Company
SE Intimation - Letter to Shareholders
Intimation of receipt of Demand Note dated 1st July, 2025
Intimation under Regulation 30 - Loss of Share Certificate Dated 2nd July, 2025
Response on Clarification on Volume Movement BSE
Press Release for Doxorubicin Hydrochloride Liposome Injection
SE Intimation SMP, 31st May, 2025
Alembic Pharmaceuticals Limited receives EIR for its API-III Facility at Karakhadi
Intimation of Investor Meet 25th June, 2025
Corporate Guarantee issued on 17th June, 2025
Intimation for Credit Rating of Enhanced Amount of CP, CRISIL
Intimation for Credit Rating of Enhanced Amount of CP, CARE
USFDA Inspection at API -I & II Facility Panelav, 31st May 2025
Press Release for Final Approval of Bosutinib Tablets 100 mg and 500 mg
Intimation of Update in Investor Meet
Press Release for Final Approval of Amlodipine and Atorvastatin Tablets
Intimation of Investor Meet, 28th May, 2025
Intimation of Investor Meet, 23rd May, 2025
Intimation under Regulation 30 Unclaimed Shares Dated 15th May, 2025
Intimation under Regulation 30 Loss of Share Certificate Dated 15th May, 2025
SE Intimation SMP, 15th May, 2025
Press Release for final approval of Rivaroxaban Tablets 2.5 mg, 10 mg, 15 mg, and 20 mg
Intimation Newspaper Publication Financial Results 7th May, 2025
Intimation Newspaper Publication, 7th May, 2025
Intimation - Appointment of Secretarial Auditors and Change in Statutory Auditors
Specimen Reminder Letter to Shareholders IEPF
Press Release for Final Approval for Ticagrelor Tablets, 90 mg and Tentative Approval for Ticagrelor Tablets, 60 mg
Alembic Pharmaceuticals Limited receives EIR for its F-2 Formulation Facility, Panelav
Commissioning of Pithampur Plant 26th April, 2025
Intimation of Investor Meet, 6th May, 2025
Intimation of BM 6th May, 2025
Intimation for Change in Email Address and Website Address of RTA of the Company
Press Release FA for Carbamazepine Tablets USP, 200 mg
Intimation under Regulation 30 Dated 3rd April, 2025
Press Release FA for Pantoprazole Sodium injection 40 mgvial (Single Dose Vial)

Qualified Institutional Placement details, disclosures, and related documentation.

Report Name Download
QIP PPD
QIP PD

Memorandum and Articles of Association governing company operations.

Report Name Download
Memorandum - Articles of Association w.e.f. 12th May, 2024
Memorandum & Articles of Association (W.e.f. 5th September, 2022)
Memorandum & Articles of Association (Upto 4th September, 2022)
Memorandum & Articles Of Association (Upto 26th July, 2018)

Downloadable annual return filings as per statutory requirements.

Report Name Download
Annual Report

Information on Aleor & APL merger arrangements and corporate restructuring.

Report Name Download
NCLT Order Sanctioning Scheme of Arrangement
Voting Results & Scrutinizer's Report NCLT CM Equity Shareholders, 14th June, 2022
Scrutinizer's Report NCLT CM Unsecured Creditors, 14th June, 2022
Scrutinizer's Report NCLT CM Secured Creditors, 14th June, 2022
Notice of Equity Shareholders
Notice of Secured Creditors
Notice of Unsecured Creditors
NCLT Order
Scheme of Arrangement
Certified Copy Of Board Resolution
Intimation Of Acquisition And Scheme Of Arrangement Of Aleor With Company 29th March, 2022
Disclosures Link
Brief profile of board of directors including directorship and full-time positions in body corporates
Details of its Business
Terms and Conditions of Appointment of Independent Directors
Composition of various Committees of Board of Directors
Code of Conduct of Board of Directors and Senior Management Personnel
Details of establishment of Vigil Mechanism / Whistle Blower Policy
Criteria of making payments to Non-Executive Directors, if the same has not been disclosed in Annual Report
Policy on dealing with Related Party Transactions
Policy for determining Material Subsidiaries
Details of familiarization programmes imparted to Independent Directors
The email address for grievance redressal and other relevant details
Contact information of the designated officials responsible for investor grievances
Financial Information including:
Notice of board meeting to discuss financial results
Financial results post-approval
Complete copy of annual report
Shareholding pattern
Details of agreements entered into with media companies or associates – Not Applicable
Schedule of analysts/investors meet and related disclosures
New and old name of the listed entity – Not Applicable
Items in sub-regulation (1) of regulation 47
All credit ratings obtained by the entity
Separate audited financial statements of each subsidiary
Secretarial compliance report as per regulation 24A(2)
Policy for determination of materiality of events or information
Contact details of key managerial personnel for determining materiality and disclosures
Disclosures under sub-regulation (8) of regulation 30
Statements of deviation(s) or variation(s) – Not Applicable
Dividend distribution policy by listed entities
Annual return as provided under section 92 of the Companies Act, 2013
Memorandum of Association and Articles of Association of the Company
Disclosures Link
Details of its Business
Composition of the Board
Financial Information including:
Notice of meeting of the board of directors where financial results shall be discussed
Financial results, on conclusion of the meeting of the board of directors where the financial results were approved
Complete copy of the annual report including balance sheet, profit and loss account, directors report, corporate governance report etc.
Contact information of the designated officials responsible for assisting and handling investor grievances
The email address for grievance redressal and other relevant details
Name of the debenture trustees with full contact details
The information, report, notices, call letters, circulars, proceedings, etc. concerning non-convertible redeemable preference shares or non-convertible debt securities
All information and reports including compliance reports filed by the listed entity
Information with respect to the following:
Default by issuer to pay interest or redemption amount – Not Applicable
Failure to create a charge on the assets – Not Applicable
All credit ratings obtained by the entity for all its listed non-convertible securities, updated immediately upon any revision in the ratings
Statements of deviation(s) or variation(s) as specified in sub-regulation (7) and (7A) of regulation 52 – Not Applicable
Annual return as provided under section 92 of the Companies Act, 2013 and the rules made thereunder

Research reports and coverage from equity research and analyst firms.

Report Name Issue Date Download
Analyst Research report w.e.f. 12th May, 2024 12th May, 2024
Analyst Research report (W.e.f. 5th September, 2022) 5th September, 2022
Analyst Research report (Upto 4th September, 2022) 4th September, 2022
Analyst Research report (Upto 26th July, 2018) 26th July, 2018

Exchange codes, ISIN numbers, and listing information.

Stock Exchange Exchange Codes ISIN Number Listed Since
NSE (National Stock Exchange) 533573 INE901L01018 20th September, 2011
BSE (Bombay Stock Exchange) APLLTD INE901L01018 20th September, 2011
Disclosures Link
SEBI Circulars on Online Dispute Resolution

Direct contact details for key managerial personnel and investor queries. Contact Details of Key Managerial Personnel (KMP's) authorized for the purpose of determining materiality pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements), 2015

Name of Key Managerial Personnel/Senior Officials Designation Contact Details
Mr. Chirayu Amin Chairman & CEO 0265 6637000
Mr. Pranav Amin Managing Director 0265 6637000
Mr. Shaunak Amin Managing Director 0265 6637000
Mr. R. K. Baheti Executive Director 0265 6637000
Mr. G. Krishnan CFO 0265 6637000
Ms. Manisha Saraf Company Secretary 0265 6637000
Mr. Nilesh Mistry Head – Accounts & Corporate Finance 0265 6637000
Mr. Ajay Kumar Desai Sr. VP-Finance 0226 6953681

For queries related to shareholder records or disclosures, contact our Investor Relations team.